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Maintenance of crestal bone level around dental implants at the implant/abutment junction (IAJ) plays an essential role in the overall success of dental implant therapy. [1] [2] [3] [4] [5] Exposure of implant surfaces due to early crestal bone loss (CBL) facilitates the accumulation and proliferation of pathogenic microbes on implant surfaces. 6, 7 Furthermore, levels of proinflammatory cytokines (such as interleukin [IL] 1 beta [β] and matrix metalloproteinase [MMP]-9) have also been reported to be significantly higher in patients with peri-implant inflammation compared to controls (patients without peri-implant inflammation). 8, 9 An increased expression of proinflammatory cytokines in the periimplant crevicular fluid (PICF) has also been associated with an increased osteoclastic activity. 10 If left unaddressed, these factors may further accelerate CBL and ultimately implant failure; however, an annual 0.1 to 0.2 mm of post-loading CBL, which occurs due to crestal bone remodeling, is considered normal. 11 No definitive treatment protocol is most effective in minimizing CBL around implants; 12 however, it has been reported that placing dental implants approximately 2 mm below the alveolar crest (subcrestal) is a useful strategy for minimizing CBL. 13 This is probably because placement of the IAJ in a subcrestal position helps minimize peri-implant soft tissue inflammation and also favors the reestablishment of a satisfactory marginal tissue architecture compared with implants placed at bone level (crestal implants). 14 Results from experimental studies on dogs have shown significantly higher CBL around crestally placed implants compared to implants placed subcrestally. 13, 15, 16 However, contradictory results have also been reported. In a recent systematic review, Al Amri reviewed 13 studies (6 clinical and 7 animal-model based) to determine whether crestal and subcrestal placement of dental implants influence crestal bone level. 17 The results showed no statistically significant difference in CBL around implants placed at crestal and subcrestal levels. 17 It is therefore hypothesized that (a) peri-implant clinical (bleeding on probing [BOP] and probing pocket depth [PPD] ) and radiographic (CBL) parameters are comparable around dental implants placed at crestal and subcrestal levels; and (b) levels of IL-1β and MMP-9 in the PICF are similar around crestally and subcrestally placed dental implants. The null hypothesis was that at 5-year follow-up period, there is no difference among dental implants placed at crestal and subcrestal levels in terms of peri-implant clinical parameters (BOP, PPD, and CBL) and levels of IL-1β and MMP-9 in the PICF.
The aim of this study was to compare changes in peri-implant inflammatory parameters (BOP, PPD, CBL, and levels of IL-1β and MMP-9 in the PICF) around crestally and subcrestally placed dental implants 5 years after implant placement.
Materials and methods

Eligibility criteria and study design
This research protocol was approved by the College of Dentistry Ethics Review Board, King Saud University. Participants were requested to sign a consent form and had the right to resign from the research project at any stage of the investigation. The eligibility criteria were as follows: (a) patients having undergone dental implant therapy for single missing tooth; (b) crestally placed single dental implants, and/or (c) subcrestally placed single dental implants. The exclusion criteria included: (a) selfreported tobacco smoking and smokeless tobacco chewing; (b) self-reported habitual alcohol use (c) self-reported systemic disorders, such as acquired immune deficiency syndrome, cancer, hepatic disorders, diabetes mellitus, cardiovascular disorders, thyroid disorders, hyperparathyroidism, gastrointestinal diseases, hypovitaminosis D, and/or renal disorders; (d) use of guided bone regeneration in the surgical site; and (e) pregnant and/or lactating females. Fifty-eight individuals, who were eligible for single implant restoration, were invited to participate in the present retrospective study; six declined to participate. The remaining 52 patients volunteered to participate in this study. Depending upon the depth of implant placement, participants were divided into two groups as follows: group 1 (n = 27): patients with dental implants placed approximately 2 mm below the alveolar crest (subcrestal); group 2 (n = 25): patients with dental implants placed at bone level (crestal).
Surgical protocol
All surgical procedures were performed under local anesthesia by one trained and experienced investigator. Full-thickness mucoperiosteal flaps were raised using a no. 15 surgical blade. In both groups, patients received platform-switched implants (Straumann AG, Basel, Switzerland) with lengths and diameters ranging from 10 to 14 mm and 3.3 to 4.1 mm, respectively. In groups 1 and 2, implants were placed 2 mm below the alveolar crest and at bone level, respectively, using a 35 Ncm insertion torque, and healing abutments were placed. All individuals were prescribed antibiotics (amoxicillin 500 mg three times daily for 7 days) and analgesics (ibuprofen 600 mg for as long as required). Oral hygiene instructions were given, and the patients were advised to start rinsing with an essential oil based mouthwash (Listerine Zero; Johnson & Johnson Middle East FZ -LLC, Dubai, UAE) twice daily for 2 weeks, after 24 hours of surgery. Full-mouth plaque and calculus debridement was performed biannually for all participants using an ultrasonic scaler (VV DENTA, Guangxi, China). Oral hygiene instructions regarding regular tooth brushing were given, and patients were encouraged to floss the teeth and peri-implant surfaces daily.
Prosthodontic protocol and prosthesis-related characteristics
In groups 1 and 2, implants were loaded after a mean healing period of 3.1 ± 0.1 and 3.2 ± 0.1 months, respectively. Master models (GC Fujirock EP die stone; GC Europe, Leuven, Belgium) were obtained from fixture-level impression using poly(vinyl siloxane) (PVS) material (Virtual; Ivoclar Vivadent AG, Schaan Liechtenstein) with an open-tray technique. Jaw relationships were recorded with a wax or silicone medium in maximum intercuspation. The stone casts were mounted in a semi-adjustable articulator. For standardization, all implants were restored with screw-retained metal ceramic (MC) crowns with full ceramic coverage to preclude the detrimental effect of extruded excess cement. Customized metal abutments (synOcta cast gold abutment; Straumann AG) were cast on using a precious gold-palladium alloy (Degubond 4; DeguDent GmbH, Hanau, Germany). The same dental laboratory fabricated all MC crowns following standard procedures. Then, crowns were torqued (35 Ncm) according to the manufacturer's recommendation before the abutment screw access channel was filled with polytetrafluoroethylene (PTFE) seal tape (Kanca Makine, Istanbul, Turkey) and light-cured composite resin (Filtek Z350 XT; 3M ESPE, St. Paul, MN). The crown occlusion was designed to harmonize with the patient's existing physiologic occlusion. Additionally, light centric contacts on the implants were obtained to minimize occlusal forces on the implant and to maximize force distribution to the adjacent natural teeth. Moreover, complete disocclusion was ensured during eccentric movements. Oral hygiene instructions and the follow-up protocol were discussed. All patients in both groups were enrolled in a biannual recall program.
Peri-implant crevicular fluid (PICF) sampling
The PICF sample collection and all clinical and radiographic examinations were performed after 5.3 ± 0.2 years of implant placement in group 1 and after 5.2 ± 0.1 years of implant placement in group 2. PICF samples were collected at approximately the same time of the day to prevent any cyclical variations from affecting the PICF volume. To avoid salivary contamination, the selected sites were isolated and dried using sterile cotton rolls. Supragingival plaque was gently removed from the implant surfaces using a sterile dry gauze, and a standardized paper strip (Periopaper; ProFlow, Inc., Amityville, NY) was inserted 1 to 2 mm into the buccal sulcus of the implant. The strip was held in place for approximately 30 seconds and transferred to a precalibrated electronic fluid quantification device (Periotron 8000; Harco Electronics, Winnipeg, Canada). Precalibration was done before each measuring session by recording a series of Periotron readings over a volume range of 0 to 1.0 μL of the PICF. The average of 5 Periotron values for the peri-implant crevicular fluid was then plotted versus the respective fluid volume. Qualitative changes in fluid composition versus Periotron Scores were also analyzed. 18 Samples were transferred to sterile Eppendorf tubes with lids (Eppendorf Safe-Lock microcentrifuge tubes T9661; Sigma-Aldrich, St. Louis, MO) and kept at -80°C until analysis. All PICF samples were assessed within 7 days of collection.
Assessment of IL-1β and MMP-9 levels
Cytokine analyses were performed by one trained investigator (Kappa 0.92). Levels of IL-1β and MMP-9 were assessed in duplicates using enzyme-linked immunosorbent assay (ELISA). Human IL-1β (Human IL-6 Quantikine R , ELISA Kit; R&D Systems Inc., Minneapolis, MN) and MMP-9 kits (Human MMP-9, Quantikine, ELISA Kit; R&D Systems Inc.) were used according to the manufacturers' instructions. A total of 100 μl diluted standards with samples were dispensed, in duplicate, into the wells coated with a specific protein antibody. The plates were incubated at room temperature for 60 minutes following which they were washed three times with a wash solution. One hundred microliters of conjugate solution was added, and the plates were incubated at room temperature for another 120 minutes. The wells were washed once again three times with a wash solution and 100 μl substrate solution was added. The plates were incubated for 20 minutes at room temperature following which 50 μl of stop solution was added to terminate color development. Absorbance was determined by reading the plate at 450 nm in a spectrophotometer (BioTek, Winooski, VT).
Assessment of peri-implant clinical and radiographic parameters
All clinical and radiographic examinations were performed after 5.3 ± 0.2 years of implant placement in group 1 and after 5.2 ± 0.1 years of implant placement in group 2. One trained investigator (Kappa 0.91) performed all clinical and radiographic evaluations. In both groups, peri-implant BOP and PPD were assessed using standard techniques. 19 These parameters were measured at six sites per implant (mesiobuccal, mid-buccal, distobuccal, distopalatal, mid-palatal, mesiopalatal). A baseline radiograph was taken immediately after implant placement to determine the original peri-implant crestal bone level. The 5-year follow-up radiograph was taken, and CBL was defined as the vertical difference in millimeters between the original periimplant bone level at baseline and that at follow-up. 20, 21 The radiographic technique was standardized using a film holder as a guiding tool for X-ray beams (Dentsply, York, PA). In each group, the mean mesial and distal CBL were recorded in millimeters on digital radiographs (Acuray 071A Intra Oral XRay System; Belmont, Hudson, FL) using a software program (Scion Image; Scion Corp., Fredrick, MD). Bleeding on probing (%)
Statistical analysis
Statistical analysis was performed using the Mann-Whitney U test (SPSS v18; SPSS Inc., Chicago, IL). Peri-implant clinical (BOP and PPD) and radiographic (CBL) parameters and levels of IL-1β and MMP-9 in PICF were statistically evaluated to determine their association with the depth of implant placement (crestal versus subcrestal dental implants). Calculation of sample size was based on the supposition that a mean difference of 0.5 mm should be detected at a significance level of 0.05 and a desired study power of 80%.
Results
General characteristics of the study population
The mean age of participants in groups 1 and 2 was 45.4 ± 1.8 (range: 25 to 64) and 43.5 ± 1.2 (range: 23 to 59) years, respectively. Male:female ratio was 11:16 in group 1 and 10:15 in group 2. In total, 52 platform-switched implants were assessed (27 implants in group 1; 25 in group 2). In group 1, 13 implants were placed in the region of missing maxillary 1st molars, and 14 implants were placed in the region of missing mandibular 1st or 2nd molars. In group 2, 10 implants were placed in the region of missing maxillary 1st or 2nd molars, and 15 implants were placed in the region of missing mandibular 1st or 2nd molars.
Clinical and radiographic parameters in groups 1 and 2
There was no statistically significant difference (P > 0.05) in mean BOP and PPD among implants in both groups at 5-year follow-up (Table 1 ). In addition, the implant location in the jaw had no effect on BOP and PPD in both groups (P > 0.05). The mean BOP and PPD around subcrestally placed implants in the maxilla and mandible were 12.6 ± 2.5% and 10.2 ± 1.9% and 2.1 ± 0.1 mm and 2.4 ± 0.1 mm, respectively. The mean BOP and PPD around crestally placed implants in the maxilla and mandible were 12.3 ± 1.7% and 14.5 ± 2.2% and 2.2 ± 0.2 mm and 2.5 ± 0.3 mm, respectively. In group 1, the overall CBL was 1.2 ± 0.2 mm. In group 2, the overall CBL was 1.4 ± 0.2 mm. There was no statistically significant difference (P > 0.05) in mean CBL around implants in both groups at 5-year follow-up (Table 1) . Furthermore, the implant location in the jaw had no effect on CBL in both groups (P > 0.05). In group 1, Table 2 Means (±standard deviations) of IL-1β and MMP-9 levels around implants in groups 1 and 2 at 5-year follow-up Group 1: Subcrestal implants (n = 27) Group 2: Crestal implants (n = 25) Not significantly different at P ˂ 0.05.
mesial and distal CBL in the maxilla and mandible were 0.8 ± 0.1 mm and 1.6 ± 0.1 mm and 1 ± 0.1 mm and 1.4 ± 0.2 mm, respectively. In group 2, mesial and distal CBL in the maxilla and mandible were 0.8 ± 0.1 mm and 1.7 ± 0.2 mm and 0.9 ± 0.3 mm and 1.6 ± 0.5 mm, respectively.
IL-1β and MMP-9 levels in groups 1 and 2
In groups 1 and 2, mean levels of IL-1β and MMP-9 in the PICF were 6.8 ± 0.5 μg/L and 7.1 ± 0.6 μg/L and 165 ± 12.2 μg/L and 187 ± 14.5 μg/L, respectively, with no significant difference between the two groups (P > 0.05). With reference to the maxilla and the mandible, there was no statistically significant difference in the levels of IL-1β and MMP-9 in the PICF of patients in both groups (P > 0.05) ( Table 2) .
Discussion
In an attempt to assess the clinical and radiographic parameters of peri-implant tissue and proinflammatory cytokine profile in the PICF among patients with dental implants placed at crestal and subcrestal levels, this study was based on two hypotheses. First, it was hypothesized that peri-implant clinical (BOP and PPD) and radiographic (CBL) inflammatory parameters are comparable around crestally and subcrestally placed dental implants. The second hypothesis was that levels of proinflammatory cytokines (IL-1β and MMP-9) in the PICF are similar around dental implants placed at crestal and subcrestal levels. The outcomes of this study are in accordance with these hypotheses, as no statistically significant differences were found between implants in both groups with reference to the aforementioned inflammatory parameters. Therefore, both hypotheses were accepted. These findings are in line with previous studies [22] [23] [24] in regard to BOP, PPD, and CBL; however, studies have yet to assess the proinflammatory cytokine profile in the PICF of dental implants placed at crestal and subcrestal levels. A variety of explanations may be posed in this regard. It is noteworthy that all participants included in this study were nonsmokers and were systemically healthy. It is well known that tobacco smoking and systemic disorders such as poorly controlled diabetes mellitus (DM) are significant risk factors for peri-implant soft tissue inflammation and CBL, as they increase the oxidative stress in oral tissues. 5, [25] [26] [27] [28] This is one explanation for the similarity in clinical and radiographic parameters among individuals in both groups. Moreover, studies [29] [30] [31] [32] [33] have shown that CBL is significantly higher around conventional implants (implants with matching platform and abutment diameters) compared with platform-switched implants (that is, the diameter of the abutment is narrower than that of the implant platform). All implants used in this study were platform-switched. It is important to mention that alveolar bone remodeling occurs after implant placement, and an annual CBL of 0.2 mm is considered normal. 11 In this study, dental implants in both groups showed <2 mm of CBL over a period of approximately 5 years, which is considered a success according to criteria reported by Albrektsson et al. 11 It is also hypothesized that there would be no statistically significant difference in CBL around implants in both groups, provided the participants continued to maintain good oral hygiene status in addition to the biannual oral hygiene maintenance program. This warrants further long-term investigations.
It is imperative that the mode of retention, customized abutment design, and healing protocol used in the current investigation may have had potential positive effects on the reported results. Screw-retained, implant-supported single restorations are more biocompatible by eliminating the detrimental effect of extruded cement on the peri-implant tissue. 34 In addition, customized abutments on single implants in the molar region can facilitate a better width for emergence profile, which might help in reducing possibility of food accumulation interdentally, and thus reduce chances of inflammation. Customized abutments also offer optimization of the margin location and the abutment alignment and geometry without the need for overcontouring. 35 In this study, implants were loaded approximately 3 months after placement using the one-stage surgical protocol, which may have affected the amount of CBL. The effect of single stage implant placement versus submerged healing has been previously investigated, showing comparable clinical and radiographic results. [36] [37] [38] [39] [40] [41] [42] [43] [44] However, peri-implant CBL has been demonstrated by others to be significantly higher in the submerged healing group. [45] [46] [47] [48] Furthermore, nonsubmerged implants resulted in higher patient satisfaction due to decreased surgical intervention. 45, 48 In a Cochrane systematic review of five randomized controlled clinical trials, 49 the one-stage approach was preferable in partially edentulous patients since it avoids one surgical intervention and shortens treatment times, while a two-stage submerged approach could be indicated when an implant has not obtained an optimal primary stability, when barriers are used for guided tissue regeneration, or when it is expected that removable interim prostheses could transmit excessive forces on the penetrating abutments. 49 IL-1β is a proinflammatory cytokine that plays a role in alveolar bone resorption by increasing osteoclastic activity 50 and also mediates oral soft tissue destruction by stimulating proteases. [50] [51] [52] Likewise, MMP-9 (also known as type IV collagenase) plays an active role in the degradation and remodeling of the extracellular matrix. 53 High concentrations of IL-1β and MMP-9 have been reported in the gingival crevicular fluid (GCF) of patients with periodontitis, 54, 55 and assessment of proinflammatory cytokines in the GCF has been proposed to have diagnostic potential for patients with periodontitis. The authors of this study suggest that assessment of proinflammatory cytokines (such as IL-1β and MMP-9) in the PICF may also hold diagnostic potential for patients with peri-implant inflammation. Therefore, assessment of PICF for the presence of proinflammatory cytokines may assist in detecting the presence of peri-implant inflammation at an early stage, which might be clinically latent. Moreover, PICF analysis may also aid in monitoring the osseointegration process and the bone response to occlusal loading and infection, thereby improving the long-term success of implants.
An interesting finding in the present investigation was that the PICF levels of IL-1β and MMP-9 were also comparable among patients in groups 1 and 2, which confirmed the clinical results. Since participants in both groups were biannually receiving dental prophylaxis in the form of mechanical plaque and calculus debridement, it is possible that levels of IL-1β and MMP-9 in the PICF did not reach a concentration at which they could augment the activity of osteoclasts; however, to our knowledge, the threshold levels of proinflammatory cytokines that would most likely induce peri-implant inflammation are yet to be determined. Accordingly, it is suggested that besides clinical examination, laboratory-based investigations (such as analysis of PICF) can also yield pertinent data regarding the occurrence and prognosis of peri-implant inflammation, particularly in susceptible individuals such as those with a history of periodontitis; however, further long-term clinical trials are needed in this regard.
In this study, BOP, PPD, CBL, and levels of IL-1β and MMP-9 were also compared in groups 1 and 2 with reference to jaw location (maxilla or mandible). No statistically significant difference was found in the aforementioned parameters with respect to implants placed in the maxilla and the mandible. An explanation in this regard may once again be associated with the routine dental prophylaxis that the participants were receiving; however, since the follow-up duration of this study was approximately 5 years, there is a possibility that there would be a difference in CBL between implants placed in the maxilla and mandible if the follow-up was for a longer period of time (e.g., 10 years or longer). This speculation has been made due to the fact that bone architecture and density varies between the maxilla and mandible. 56 A limitation of this study is that all participants were nonsmokers and systemically healthy, which may have been a source of bias. Moreover, the mean age of participants in both groups lies in the middle-aged group. There is a possibility that soft tissue inflammation, CBL, and levels of proinflammatory cytokines in the PICF are higher in elderly patients (such as those ࣙ70 years), tobacco smokers, and patients with systemic diseases such as poorly controlled DM. In addition, the distribution of men and women in both groups was not comparable. The hormonal changes in women (particularly in the postmenopausal phase) may influence the clinical and radiographic parameters of peri-implant inflammation and levels of proinflammatory cytokines in the PICF as compared to men. Another limitation is that the information about minimum PICF levels of IL-1β and MMP-9 that would most likely be associated with peri-implant inflammation is lacking. Therefore, it was assumed that since there was no clinical evidence of peri-implant inflammation around implant restorations in both groups, the reported PICF concentrations of IL-1β and MMP-9 are below concentrations that would have augmented peri-implant inflammation. Further studies are required to estimate the threshold levels of proinflammatory cytokines that would most likely induce peri-implant inflammation. Furthermore, assessment of CBL was based on the evaluation of 2D radiographs. Additional studies based on 3D computed tomographic analysis may yield valuable information regarding the patterns of alveolar bone remodeling around crestally and subcrestally placed dental implants. Finally, it is essential to emphasize that the present investigation focuses on single implant restorations where biomechanical forces are different, and removal of excess cement by the clinician, passivity of fit, and oral hygiene maintenance by the patient are easier compared to multiunit implant-supported prostheses (ISP). Further longterm randomized controlled clinical trials are required to investigate these parameters around multiunit and cement-retained ISP.
Conclusions
Within the limitations of this 5-year retrospective study, it can be concluded that:
1. Clinical, radiographic, and immunologic inflammatory parameters are comparable around dental implants placed at crestal and subcrestal levels. 2. The depth of implant placement appears to have no effect on clinical status and performance of single implant restorations up to 5 years after placement.
